The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE−/− mice fed a western diet

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Diabetologia

• Publication date

  2017-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s00125-016-4158-2PMID 27866224
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

  2016influential reference
• Empagliflozin, via Switching Metabolism Toward Lipid Utilization, Moderately Increases LDL Cholesterol Levels Through Reduced LDL Catabolism

  2016cited by this paper
• Pathophysiology of lipid droplet proteins in liver diseases.

  2016cited by this paper
• Fibrates for secondary prevention of cardiovascular disease and stroke.

  2015cited by this paper
• Mechanistic link between nonalcoholic fatty liver disease and cardiometabolic disorders.

  2015cited by this paper
• Amelioration of Hyperglycemia with a Sodium-Glucose Cotransporter 2 Inhibitor Prevents Macrophage-Driven Atherosclerosis through Macrophage Foam Cell Formation Suppression in Type 1 and Type 2 Diabetic Mice

  2015cited by this paper
• Effect of a new PPAR-gamma agonist, lobeglitazone, on neointimal formation after balloon injury in rats and the development of atherosclerosis.

  2015cited by this paper
• Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.

  2015cited by this paper
• Effect of Repetitive Glucose Spike and Hypoglycaemia on Atherosclerosis and Death Rate in Apo E-Deficient Mice

  2015cited by this paper
• Adipokines, diabetes and atherosclerosis: an inflammatory association

  2015cited by this paper
• The mechanisms and therapeutic potential of SGLT2 inhibitors in diabetes mellitus.

  2015cited by this paper
• Identification of cardiometabolic risk: visceral adiposity index versus triglyceride/HDL cholesterol ratio.

  2014cited by this paper
• Efficacy and safety of empagliflozin for type 2 diabetes: a systematic review and meta‐analysis

  2014cited by this paper
• Hepatic trans-Golgi action coordinated by the GTPase ARFRP1 is crucial for lipoprotein lipidation and assembly[S]

  2014cited by this paper
• Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.

  2014cited by this paper
• Impact of MCP-1 in atherosclerosis.

  2014cited by this paper
• Metformin Inhibits Monocyte-to-Macrophage Differentiation via AMPK-Mediated Inhibition of STAT3 Activation: Potential Role in Atherosclerosis

  2014cited by this paper
• Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients.

  2014cited by this paper
• Modulation of adiponectin as a potential therapeutic strategy.

  2014cited by this paper
• Dapagliflozin compared with other oral anti‐diabetes treatments when added to metformin monotherapy: a systematic review and network meta‐analysis

  2014cited by this paper
• C‐reactive protein promotes atherosclerosis by increasing LDL transcytosis across endothelial cells

  2014cited by this paper
• Sodium-Glucose Cotransporter 2 Inhibition and Glycemic Control in Type 1 Diabetes: Results of an 8-Week Open-Label Proof-of-Concept Trial

  2014cited by this paper
• Cardiovascular and hemodynamic effects of glucagon-like peptide-1

  2014cited by this paper
• Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise

  2013cited by this paper
• A Phase IIb, randomized, placebo‐controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes

  2013cited by this paper
• Effects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db mice.

  2012cited by this paper
• Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin.

  2012cited by this paper
• Effect of a Dipeptidyl Peptidase-IV Inhibitor, Des-Fluoro-Sitagliptin, on Neointimal Formation after Balloon Injury in Rats

  2012cited by this paper
• Stress Augments Insulin Resistance and Prothrombotic State

  2012cited by this paper
• Stress augments insulin resistance and prothrombotic state : role of visceral adipose-derived monocyte chemoattractant protein-1

  2012cited by this paper
• TS‐071 is a novel, potent and selective renal sodium‐glucose cotransporter 2 (SGLT2) inhibitor with anti‐hyperglycaemic activity

  2011cited by this paper
• Effect of S-adenosylmethionine on neointimal formation after balloon injury in obese diabetic rats.

  2011cited by this paper
• Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.

  2010cited by this paper
• Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure

  2010cited by this paper
• Modulation of lipid droplet size and lipid droplet proteins by trans-10,cis-12 conjugated linoleic acid parallels improvements in hepatic steatosis in obese, insulin-resistant rats.

  2010cited by this paper
• Dapagliflozin, a Novel, Selective SGLT2 Inhibitor, Improved Glycemic Control Over 2 Weeks in Patients With Type 2 Diabetes Mellitus

  2009cited by this paper
• Abstract 1559: Reduced Adipose Tissue Inflammation Represents an Intermediate Cardiometabolic Phenotype in Obesity

  2009cited by this paper
• Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes.

  2009cited by this paper
• Sodium–glucose co‐transporter‐2 inhibitors: an emerging new class of oral antidiabetic drug

  2009cited by this paper
• Adipose Macrophage Infiltration Is Associated With Insulin Resistance and Vascular Endothelial Dysfunction in Obese Subjects

  2008cited by this paper
• Sodium-Glucose Cotransport Inhibition With Dapagliflozin in Type 2 Diabetes

  2008cited by this paper
• Diabetic atherosclerosis mouse models.

  2007cited by this paper
• Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.

  2006cited by this paper
• Phlorizin: a review

  2005cited by this paper
• Monocyte and macrophage heterogeneity

  2005cited by this paper
• Adiponectin expression from human adipose tissue: relation to obesity, insulin resistance, and tumor necrosis factor-alpha expression.

  2003cited by this paper
• Role of adipocytokines on the pathogenesis of atherosclerosis in visceral obesity.

  1999cited by this paper
• The human kidney low affinity Na+/glucose cotransporter SGLT2. Delineation of the major renal reabsorptive mechanism for D-glucose.

  1994cited by this paper
• Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression.

  1991cited by this paper
• Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man

  1985cited by this paper
• THE ACTION OF PHLORIZIN ON THE EXCRETION OF GLUCOSE, XYLOSE, SUCROSE, CREATININE AND UREA BY MAN.

  1933cited by this paper

• Timing-dependent anti-inflammatory effects of empagliflozin in monocyte-derived macrophages from post-myocardial infarct patients with type 2 diabetes

  2026cites this paper
• Loss of Beta‐Cell Identity and Function as a Mechanism of Secondary Failure of Sulfonylurea Therapy in Diabetes

  2026cites this paper
• Molecular mechanisms and therapeutic progress in atherosclerosis: bridging immune inflammation and precision medicine

  2026cites this paper
• Clinical knowns and mechanistic unknowns: cardioprotection and inflammation modulation of GLP-1 receptor agonists and SGLT2 inhibitors.

  2026cites this paper
• Nephroprotective Mechanisms of SGLT2i: Beyond the Glucose-Lowering Effect

  2025cites this paper
• FABP4 inhibition protects renal tubular cells and ameliorates renal inflammation in diabetic kidney disease.

  2025cites this paper
• Update on the Efficacy and Safety of Sodium–Glucose Co-Transporter 2 Inhibitors in Patients with Chronic Diseases: A Systematic Review and Meta-Analysis

  2025cites this paper
• Diabetes and calcific aortic valve disease: implications of glucose-lowering medication as potential therapy

  2025cites this paper
• In Search of Commonality: Physiological and Therapeutic Potentials of Sodium-Glucose Transport Protein 2 Inhibitors in Cardiovascular and Chronic Kidney Diseases

  2025cites this paper
• A critical review on SGLT2 inhibitors for diabetes mellitus, renal health, and cardiovascular conditions.

  2025cites this paper
• Empagliflozin slows down natural kidney senescence via Six1/Wnt4/NF-κB pathway

  2025cites this paper
• Canagliflozin-driven cellular re-differentiation and migration inhibition in vascular smooth muscle cells via PTEN upregulation

  2025cites this paper
• The potential neuroprotective effect of empagliflozin against depressive-like behavior induced by chronic unpredictable mild stress in rats: Involvement of NLRP3 inflammasome.

  2025cites this paper
• Stress Hyperglycemia as a Prognostic Indicator of the Clinical Outcomes in Patients with Stroke: A Comprehensive Literature Review

  2025cites this paper
• Empagliflozin versus metformin for glucose variability and metabolic outcomes in drug-naïve type 2 diabetes: The EMPA-FIT study.

  2025cites this paper
• Cardiometabolic and renal benefits of sodium–glucose cotransporter 2 inhibitors

  2025cites this paper
• Serum amyloid A in HFpEF and cardiometabolic diseases

  2025influential citation
• The Impact of Sodium Glucose Co-Transporter 2 (SGLT-2) Inhibitors on Atherogenesis: A Systematic Review of Experimental and Clinical Evidence

  2025cites this paper
• A study of SGLT2 inhibitors on levels of plasma atherogenesis biomarkers in diabetes

  2024cites this paper
• The effect of sodium‐glucose cotransporter‐2 inhibitors on inflammatory biomarkers: A meta‐analysis of randomized controlled trials

  2024cites this paper
• It’s Time for New Insights into Renovascular Hypertension at the Molecular Level

  2024cites this paper
• SGLT2 inhibitor improves the prognosis of patients with coronary heart disease and prevents in-stent restenosis

  2024cites this paper
• Sodium-glucose cotransporter protein 2 inhibition, plasma proteins, and ischemic stroke: A mediation Mendelian randomization and colocalization study.

  2024cites this paper
• Empagliflozin Dampens Doxorubicin-Induced Chemobrain in Rats: The Possible Involvement of Oxidative Stress and PI3K/Akt/mTOR/NF-κB/TNF-α Signaling Pathways

  2024cites this paper
• Progress in the Study of the Effect of SGLT-2 Inhibitors on Ischemic Stroke and Its Mechanism of Action

  2024cites this paper
• The Potential Impact of SGLT2-I in Diabetic Foot Prevention: Promising Pathophysiologic Implications, State of the Art, and Future Perspectives—A Narrative Review

  2024cites this paper
• Canagliflozin Alleviates Atherosclerosis Progression through Inflammation, Oxidative Stress, and Autophagy in Western Diet-fed ApoE−/− Mice

  2024cites this paper
• Dapagliflozin improves the dysfunction of human umbilical vein endothelial cells (HUVECs) by downregulating high glucose/high fat-induced autophagy through inhibiting SGLT-2.

  2024cites this paper
• SGLT2 inhibitors: from glucose-lowering to cardiovascular benefits

  2024cites this paper
• Empagliflozin Attenuates Neointima Formation After Arterial Injury and Inhibits Smooth Muscle Cell Proliferation and Migration by Suppressing Platelet‐Derived Growth Factor–Related Signaling

  2024cites this paper
• Empagliflozin attenuates epithelial to mesenchymal transition through senescence in peritoneal dialysis.

  2024cites this paper
• SGLT2 Inhibitors Empagliflozin and Canagliflozin Ameliorate Allergic Asthma Responses in Mice

  2024cites this paper
• The effect of Empagliflozin on echocardiographic parameters in diabetic patients after acute myocardial infarction: A systematic review and meta-analysis with trial sequential analysis

  2024cites this paper
• Empagliflozin attenuates radiation-induced hematopoietic damage via NOX-4/ROS/p38 pathway.

  2024cites this paper
• SGLT1 and SGLT2 inhibition, circulating metabolites, and cerebral small vessel disease: a mediation Mendelian Randomization study

  2024cites this paper
• Longitudinal assessment of coronary plaque regression related to sodium–glucose cotransporter-2 inhibitor using coronary computed tomography angiography

  2024cites this paper
• Mitigating Vascular Inflammation by Mimicking AIBP Mechanisms: A New Therapeutic End for Atherosclerotic Cardiovascular Disease

  2024cites this paper
• Similarities and Differences of Vascular Calcification in Diabetes and Chronic Kidney Disease

  2024cites this paper
• The alleviative effects of canagliflozin on imiquimod-induced mouse model of psoriasis-like inflammation

  2024cites this paper
• The Role of Sodium Glucose Co-Transporter 2 Inhibitors in Atrial Fibrillation: A Comprehensive Review

  2024cites this paper
• Systemic and organ-specific anti-inflammatory effects of sodium-glucose cotransporter-2 inhibitors.

  2024cites this paper
• Protective Mechanisms of SGLTi in Ischemic Heart Disease

  2024cites this paper
• Evaluation of empagliflozin efficacy as a promising anti-aging treatment in mice: In-vivo study

  2024cites this paper
• Protective effects of imeglimin on the development of atherosclerosis in ApoE KO mice treated with STZ

  2024cites this paper
• SGLT2 Inhibitors and How They Work Beyond the Glucosuric Effect. State of the Art

  2024cites this paper
• Effects of Glucagon-Like Peptide-1 Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors on Intima-Media Thickness: Systematic Review and Meta-Analysis

  2024cites this paper
• Arterial Hypertension: Novel Pharmacological Targets and Future Perspectives

  2024cites this paper
• Research Progress of Sodium-Glucose Cotransporter 2 Inhibitor in the Treatment of Polycystic Ovary Syndrome

  2024cites this paper
• Development, optimization, and evaluation of Empagliflozin nanoemulsion for the management of neuroinflammation associated Alzheimer's disease

  2024cites this paper
• Is It Time for a New Algorithm for the Pharmacotherapy of Steroid-Induced Diabetes?

  2024cites this paper
• Sodium–Glucose Cotransporter Protein 2 Inhibitors: Novel Application for the Treatment of Obesity-Associated Hypertension

  2024cites this paper
• Role of canagliflozin in ameliorating isoprenaline induced cardiomyocyte oxidative stress via the heme oxygenase-1 mediated pathway

  2023cites this paper
• Empagliflozin reduces neointimal formation and vascular smooth muscle cell proliferation via the suppression of PDGF-related signaling

  2023cites this paper
• SGLT2 Inhibitors in Aging-Related Cardiovascular Disease: A Review of Potential Mechanisms

  2023cites this paper
• Cardioprotective Effects of Sodium Glucose Cotransporter 2 Inhibition in Angiotensin II-Dependent Hypertension Are Mediated by the Local Reduction of Sympathetic Activity and Inflammation

  2023cites this paper
• Diabetes-Alzheimer's connection in older age: SGLT2 inhibitors as promising modulators of disease pathways.

  2023cites this paper
• Empagliflozin treatment of cardiotoxicity: A comprehensive review of clinical, immunobiological, neuroimmune, and therapeutic implications.

  2023cites this paper
• Cardiovascular Diseases: Therapeutic Potential of SGLT-2 Inhibitors

  2023cites this paper
• Diabetes as one of the long-term COVID-19 complications: from the potential reason of more diabetic patients’ susceptibility to COVID-19 to the possible caution of future global diabetes tsunami

  2023cites this paper
• Current understanding on pathogenesis and effective treatment of glycogen storage disease type Ib with empagliflozin: new insights coming from diabetes for its potential implications in other metabolic disorders

  2023cites this paper
• The role of SGLT2i in attenuating residual cardiovascular risk through blood pressure-lowering: mechanistic insights and perspectives

  2023cites this paper
• Immunomodulatory Effects of SGLT2 Inhibitors—Targeting Inflammation and Oxidative Stress in Aging

  2023cites this paper
• The SGLT2 Inhibitor Canagliflozin Reduces Atherosclerosis by Enhancing Macrophage Autophagy

  2023cites this paper
• The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Heart Failure Management: The Continuing Challenge of Clinical Outcome Endpoints in Heart Failure Trials

  2023cites this paper
• Protection of diabetes in aortic abdominal aneurysm: Are antidiabetics the real effectors?

  2023cites this paper
• Treatment of diabetic kidney disease. A network meta-analysis

  2023cites this paper
• Anti‐inflammatory effects of sodium‐glucose cotransporter‐2 inhibitors in COVID‐19

  2023cites this paper
• Empagliflozin reduces endoplasmic reticulum stress associated TXNIP/NLRP3 activation in tunicamycin-stimulated aortic endothelial cells

  2023cites this paper
• Therapy Combining Glucagon-Like Peptide-1 Receptor Agonist with Sodium-Glucose Cotransporter 2 Inhibitor Suppresses Atherosclerosis in Diabetic ApoE-Deficient Mice

  2023cites this paper
• Design expert software assisted development and evaluation of empagliflozin and sitagliptin combination tablet with improved in-vivo anti-diabetic activities

  2023cites this paper
• Comparison of Weight Reduction, Change in Parameters and Safety of a Very Low Carbohydrate Diet in Comparison to a Low Carbohydrate Diet in Obese Japanese Subjects with Metabolic Disorders

  2023cites this paper
• What Do We Know about Flozins: New, Pleiotropic Drugs

  2023cites this paper
• The Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitor Empagliflozin Reverses Hyperglycemia-Induced Monocyte and Endothelial Dysfunction Primarily through Glucose Transport-Independent but Redox-Dependent Mechanisms

  2023cites this paper
• Empagliflozin ameliorates atherosclerosis via regulating the intestinal flora.

  2023cites this paper
• Research progress on the effects of novel hypoglycemic drugs in diabetes combined with myocardial ischemia/reperfusion injury.

  2023cites this paper
• Cognitive benefits of Sodium-Glucose Co-Transporters-2 Inhibitors in the Diabetic Milieu.

  2023cites this paper
• The effect of sodium-glucose co-transporter-2 inhibitors on markers of subclinical atherosclerosis

  2023cites this paper
• Empagliflozin alleviates the development of autoimmune myocarditis via inhibiting NF-κB-dependent cardiomyocyte pyroptosis.

  2023cites this paper
• The comparison of the antidiabetic effects of exenatide, empagliflozin, quercetin, and combination of the drugs in type 2 diabetic rats

  2023cites this paper
• SGLT‐2 inhibitors enhance the effect of metformin to ameliorate hormonal changes and inflammatory markers in a rat PCOS model

  2023cites this paper
• A review of stress-induced hyperglycaemia in the context of acute ischaemic stroke: Definition, underlying mechanisms, and the status of insulin therapy

  2023cites this paper
• Combination Therapy of RAS Inhibition and SGLT2 Inhibitors Decreases Levels of Endotrophin in Persons with Type 2 Diabetes

  2023cites this paper
• COVID-19: Diabetes Perspective—Pathophysiology and Management

  2023cites this paper
• Empagliflozin: Potential Protective Effects on Hepatocytes and Liver Outcomes in Streptozotocin -Diabetic Rats.

  2023cites this paper
• Cardiovascular protection by SGLT2 inhibitors – Do anti-inflammatory mechanisms play a role?

  2022cites this paper
• Impact of sodium glucose cotransporter-2 inhibitors on liver steatosis/fibrosis/inflammation and redox balance in non-alcoholic fatty liver disease

  2022cites this paper
• Empagliflozin mitigates endothelial inflammation and attenuates endoplasmic reticulum stress signaling caused by sustained glycocalyx disruption

  2022cites this paper
• The impact of SGLT2 inhibitors on inflammation: A systematic review and meta-analysis of studies in rodents.

  2022cites this paper
• Can sodium-glucose co-transporter-2 (SGLT-2) inhibitor reduce the risk of adverse complications due to COVID-19? – Targeting hyperinflammation

  2022cites this paper
• Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Regulation of Inflammatory Processes in Animal Models

  2022cites this paper
• Association of Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitor Use With Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus Patients With Stabilized Acute Myocardial Infarction: A Propensity Score Matching Study

  2022cites this paper
• Geroscience‐guided repurposing of FDA‐approved drugs to target aging: A proposed process and prioritization

  2022cites this paper
• Characteristics and molecular mechanisms through which SGLT2 inhibitors improve metabolic diseases: A mechanism review.

  2022cites this paper
• Dapagliflozin induces vasodilation in resistance-size mesenteric arteries by stimulating smooth muscle cell KV7 ion channels

  2022cites this paper
• Repurposing SGLT2 Inhibitors for Neurological Disorders: A Focus on the Autism Spectrum Disorder

  2022influential citation
• Old and Novel Therapeutic Approaches in the Management of Hyperglycemia, an Important Risk Factor for Atherosclerosis

  2022cites this paper
• Effect of ipragliflozin on carotid intima-media thickness in patients with type 2 diabetes: a multicenter, randomized, controlled trial

  2022cites this paper
• Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition

  2022cites this paper
• Sodium-Glucose Cotransporter-2 Inhibitors: Impact on Atherosclerosis and Atherosclerotic Cardiovascular Disease Events.

  2022cites this paper
• Antidiabetic agents: Do they hit the right targets?

  2022cites this paper